Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastrografin in CRE-induced SBO
NCT03642288Unknown
- Sponsor
- Jinling Hospital
- Start
- Apr 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
01
Overview
Open-label trial of diatrizoate meglumine + diatrizoate sodium in small bowel obstruction (SBO), sponsored by Jinling Hospital. Primary endpoint: Rate of successful conservative treatment at 5 days. Status: unknown.
02
Drugs
diatrizoate meglumine + diatrizoate sodium
03
Conditions
small bowel obstruction (SBO)
Beyond the preview
Go deeper on NCT03642288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642288.